Dr. Jan Philipp Bewersdorf, MD

Dr. Bewersdorf practices at Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut.

Dr. Bewersdorf's NPI, 1174013601, was assigned on May 10, 2018. Dr. Bewersdorf graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 2017. Dr. Bewersdorf holds Connecticut license 75829.

Dr. Bewersdorf's primary practice is Yale New Haven Psychiatric Hospital (York St), at 20 York Street, New Haven, CT 06510. The practice phone is (203) 688-5900.

Dr. Bewersdorf's primary practice is Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut. Dr. Bewersdorf is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Bewersdorf to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bewersdorf practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bewersdorf's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bewersdorf is licensed in Connecticut.

CMS data shows 46 Medicare services from Dr. Bewersdorf across 1 procedure code in 2024, for 29 Medicare patients. Medicare paid $2,950 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 29 Medicare patients who saw Dr. Bewersdorf in 2024. The largest group is 65 to 74, with 12 patients. 75% of them have high blood pressure, and 72% have high cholesterol. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bewersdorf's median patient age at 72, with 37% women.

In 2024, Dr. Bewersdorf wrote 108 Medicare Part D claims for 23 patients. 69% of them were for generic drugs. CMS names the drug for 43 of them, across 3 drugs with 11 or more claims each, at $72,405 in total drug cost. In 2023, CMS named 17 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Bewersdorf for performance year 2024, reported as part of a group. Dr. Bewersdorf accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bewersdorf as offering telehealth.

Dmand AI links 129 papers to Dr. Bewersdorf, published from 2017 to 2025. 2020 was the busiest year, with 18. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation. Dr. Bewersdorf has published most often in Leuk Lymphoma. Dr. Bewersdorf's most frequent co-authors are Amer Zeidan, Nikolai Alexandrovich Podoltsev, MD, PhD and Stephanie Halene, MD.

CMS Open Payments shows 3 general payments to Dr. Bewersdorf from 2 drug and device companies in 2024. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $90.

Dr. Bewersdorf graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 2017.